© All rights reserved to Barnea Jaffa Lande & Co. Law offices

Regulation / Healthcare Regulatory

Life-science companies, whether global corporations or startups, are forced to operate in a highly regulated industry. This often creates complex legal challenges.

Improper application of regulatory requirements may prolong a company’s product’s go-to-market, thereby affecting both return on investment and patient health. It may also have legal implications.

 

Understanding the importance of regulation, Barnea strives to provide comprehensive legal regulatory services to Israeli and foreign companies operating in the healthcare field. We represent clients working in biotechnology, medical instrumentation, pharmaceuticals, diagnostic instrumentation, imaging, and more.

 

Our counsel covers both legal and regulatory issues, including intellectual property, privacy, and consumer protection. We also accompany clients in the process of adjusting and assimilating changes to regulatory requirements.

 

We offer companies services that span across R&D, product registration, licensing and grant applications, and distribution and marketing.

 

Back to Regulation

News and updates - Regulation / Healthcare Regulatory:


January 2, 2019

"High" Companies

The Israel Securities Authority published an announcement to investors with various emphases about public companies operating in the medical cannabis market. Its announcement calls investors’ attention to several parameters they should consider when deciding whether to invest in securities of public companies operating, or expecting to begin operating, in the medical cannabis market.

January 1, 2019

Amendment to Hazardous Drugs Ordinance Promotes Regulation in Cannabis Market

On December 25, 2018, the Israeli parliament approved the second and third readings of an amendment to the Hazardous Drugs Ordinance (Delegation of Supervisory and Enforcement Authorities Relating to Cannabis for Medicinal and Research Purposes).

November 29, 2018

French Tech Tour – Healthcare Delegation

We hosted today a delegation of French startup companies from the life sciences and medtech sectors. The delegation was organized by the Embassy of France and visited Israel to learn about the local life sciences scene. During the event, Adv. Ariella Dreyfuss discussed the Israeli medtech ecosystem and the legal challenges companies should be aware of.

Regulation / Healthcare Regulatory

Life-science companies, whether global corporations or startups, are forced to operate in a highly regulated industry. This often creates complex legal challenges.

Improper application of regulatory requirements may prolong a company’s product’s go-to-market, thereby affecting both return on investment and patient health. It may also have legal implications.

 

Understanding the importance of regulation, Barnea strives to provide comprehensive legal regulatory services to Israeli and foreign companies operating in the healthcare field. We represent clients working in biotechnology, medical instrumentation, pharmaceuticals, diagnostic instrumentation, imaging, and more.

 

Our counsel covers both legal and regulatory issues, including intellectual property, privacy, and consumer protection. We also accompany clients in the process of adjusting and assimilating changes to regulatory requirements.

 

We offer companies services that span across R&D, product registration, licensing and grant applications, and distribution and marketing.

 

Back to Regulation

News and updates - Regulation:


January 2, 2019

"High" Companies

The Israel Securities Authority published an announcement to investors with various emphases about public companies operating in the medical cannabis market. Its announcement calls investors’ attention to several parameters they should consider when deciding whether to invest in securities of public companies operating, or expecting to begin operating, in the medical cannabis market.

January 1, 2019

Amendment to Hazardous Drugs Ordinance Promotes Regulation in Cannabis Market

On December 25, 2018, the Israeli parliament approved the second and third readings of an amendment to the Hazardous Drugs Ordinance (Delegation of Supervisory and Enforcement Authorities Relating to Cannabis for Medicinal and Research Purposes).

November 29, 2018

French Tech Tour – Healthcare Delegation

We hosted today a delegation of French startup companies from the life sciences and medtech sectors. The delegation was organized by the Embassy of France and visited Israel to learn about the local life sciences scene. During the event, Adv. Ariella Dreyfuss discussed the Israeli medtech ecosystem and the legal challenges companies should be aware of.

Enter your email for newsletter sign up: